Published in AIDS on October 01, 2005
Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci (2009) 1.58
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry (2012) 1.41
Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun (2009) 1.31
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun (2008) 1.30
Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci (2007) 1.10
Brain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopy. Int J Clin Exp Med (2012) 1.07
Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res (2010) 1.01
Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol (2010) 0.97
Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci (2015) 0.96
Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology (2011) 0.95
Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci (2009) 0.92
Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment. J Neurovirol (2014) 0.89
Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci (2007) 0.87
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. Curr Neuropharmacol (2016) 0.83
A mitochondrial bioenergetic basis of depression. J Bioenerg Biomembr (2014) 0.81
Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Am J Gastroenterol (2010) 0.80
Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence. Hepat Mon (2011) 0.80
Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices. Gen Hosp Psychiatry (2009) 0.79
Association of Baseline Sleep Quality With Trajectories of Depressive Symptoms in Patients Undergoing Interferon Treatment. Psychosom Med (2015) 0.78
Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery. Int J Neuropsychopharmacol (2016) 0.78
Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment. Ann Gastroenterol (2015) 0.77
An altered peripheral IL6 response in major depressive disorder. Neurobiol Dis (2016) 0.77
Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort. Antivir Ther (2013) 0.76
Psychiatric clearance for patients started on interferon-alpha-based therapies. Am J Psychiatry (2013) 0.75
The Effect of Combination Antiviral Therapy in the Treatment of Hepatitis C on the Occurrence of Depressive Disorder in Patients Treated for Hepatitis C in the Republic of Srpska. Med Arch (2016) 0.75
Hepatitis C virus antibody titers associated with cognitive dysfunction in an asymptomatic community-based sample. J Clin Exp Neuropsychol (2016) 0.75
Uveitic macular edema. Eye (Lond) (2016) 0.75
Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin. J Neurovirol (2016) 0.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci (2002) 2.69
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. Psychol Bull (2007) 2.25
Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry (2004) 2.23
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
The role of executive functioning in CBT: a pilot study with anxious older adults. Behav Res Ther (2005) 1.97
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry (2006) 1.79
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry (2005) 1.71
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology (2010) 1.70
Paternal age and risk of schizophrenia in adult offspring. Am J Psychiatry (2002) 1.69
The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry (2004) 1.59
Resting neural activity distinguishes subgroups of schizophrenia patients. Biol Psychiatry (2004) 1.51
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Neuropsychological differences between late-onset and recurrent geriatric major depression. Am J Psychiatry (2005) 1.41
Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. J Psychiatr Res (2002) 1.40
Facial expressiveness in patients with schizophrenia compared to depressed patients and nonpatient comparison subjects. Am J Psychiatry (2005) 1.39
Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis C. AIDS Read (2003) 1.38
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1. AIDS Read (2006) 1.38
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry (2002) 1.29
Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol (2008) 1.29
Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol (2013) 1.25
Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder. J Consult Clin Psychol (2007) 1.21
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology (2006) 1.20
Visual backward-masking deficits in schizophrenia: relationship to visual pathway function and symptomatology. Schizophr Res (2003) 1.19
Odor identification, eye tracking and deficit syndrome schizophrenia. Biol Psychiatry (2002) 1.15
Developing novel treatments for mood disorders: accelerating discovery. Biol Psychiatry (2002) 1.13
A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry (2003) 1.10
Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapy. J Clin Psychiatry (2008) 1.10
Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates. Psychiatry Res (2011) 1.09
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis (2012) 1.08
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses (2010) 1.08
Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry (2005) 1.07
Diphenoxylate hydrochloride dependency. J Psychiatr Pract (2007) 1.07
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci (2004) 1.04
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res (2006) 1.04
Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol (2005) 1.01
Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depress Anxiety (2009) 1.01
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis (2003) 1.00
Symptoms of posttraumatic stress disorder in patients who have had a myocardial infarction. Psychosomatics (2006) 1.00
Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry (2003) 0.99
Synchronized maternal-infant elevations of primate CSF CRF concentrations in response to variable foraging demand. CNS Spectr (2005) 0.99
Molecular targets in the treatment of anxiety. Biol Psychiatry (2002) 0.99
Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry (2007) 0.98
Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry (2004) 0.98
Source monitoring impairments in schizophrenia: characterisation and associations with positive and negative symptomatology. Psychiatry Res (2002) 0.98
Cost-efficacy of individual and combined treatments for panic disorder. J Clin Psychiatry (2007) 0.97
Rodent doxapram model of panic: behavioral effects and c-Fos immunoreactivity in the amygdala. Biol Psychiatry (2003) 0.97
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr (2008) 0.97
Early-life stress, corticotropin-releasing factor, and serotonin transporter gene: a pilot study. Psychoneuroendocrinology (2010) 0.96
HIV and liver diseases: recent clinical advances. Clin Liver Dis (2005) 0.96
The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates. Neurosci Lett (2010) 0.96
The human dimension: how the prefrontal cortex modulates the subcortical fear response. Rev Neurosci (2007) 0.95
Management of chronic hepatitis C virus in patients with HIV. Curr Treat Options Gastroenterol (2005) 0.95
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2004) 0.95
Does maintenance CBT contribute to long-term treatment response of panic disorder with or without agoraphobia? A randomized controlled clinical trial. J Consult Clin Psychol (2012) 0.95
Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm. J Infect Dis (2013) 0.94
Chronic antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry (2012) 0.93
Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder. J Consult Clin Psychol (2005) 0.93
An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics. Biol Psychiatry (2002) 0.93
The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch (2010) 0.93
Patient characteristics and variability in adherence and competence in cognitive-behavioral therapy for panic disorder. J Consult Clin Psychol (2013) 0.93
HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next? Clin Infect Dis (2013) 0.93
Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety (2011) 0.93
Citalopram-induced diplopia. Psychosomatics (2005) 0.93
Effect of medication and psychotherapy on heart rate variability in panic disorder. Depress Anxiety (2009) 0.92
Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits. Schizophr Res (2004) 0.92
Early-life stress and neurometabolites of the hippocampus. Brain Res (2010) 0.92
Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder. Am J Psychiatry (2005) 0.91
Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep (2006) 0.91
Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res (2003) 0.91
Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis (2013) 0.90
Advances in the treatment of anxiety: targeting glutamate. NeuroRx (2006) 0.90
Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry (2004) 0.90
Differing concentrations of corticotropin-releasing factor and oxytocin in the cerebrospinal fluid of bonnet and pigtail macaques. Psychoneuroendocrinology (2002) 0.89
Rater bias in a blinded randomized placebo-controlled psychiatry trial. Stat Med (2006) 0.89
Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry (2006) 0.89
The neurobiology of postpartum depression. CNS Spectr (2005) 0.89
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2002) 0.89
Antidepressant adherence and suicide risk in depressed youth. Am J Psychiatry (2005) 0.88
Attrition in a multicenter clinical trial for panic disorder. J Nerv Ment Dis (2010) 0.88
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis (2012) 0.88
Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early trauma. Psychiatry Res (2006) 0.87
Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways. J Autoimmun (2013) 0.87
The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin Liver Dis (2011) 0.86
Auditory abnormalities in autism: toward functional distinctions among findings. CNS Spectr (2005) 0.86
The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol (2011) 0.86
Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin. Rev Gastroenterol Disord (2004) 0.86